SGLT2 inhibitors and outcomes in the chronic Post-LVAD phase: a multicenter real-world cohort study
Abstract
Background The effect of sodium–glucose cotransporter-2 inhibitors (SGLT2i) in patients with left ventricular assist devices (LVAD) remains uncertain. We evaluated the association between SGLT2i use and adverse outcomes during the chronic post-LVAD phase. Methods We conducted a retrospective cohort study using the TriNetX network. Adults with LVAD implantation (2014–2025) who survived ≥90 days were included. SGLT2i exposure (empagliflozin or dapagliflozin) was identified by prescription records. A prespecified 90-day delayed outcome window defined follow-up from 3 months to 1 year after the index date. The primary outcome was a composite of all-cause mortality or heart failure exacerbation (HFE). Secondary outcomes included HFE, all-cause mortality, and major adverse kidney events (MAKE). Propensity score matching (1:1) and Cox regression were applied. Results After matching, 1,318 patients were included in each group. SGLT2i use was associated with a lower risk of the primary composite endpoint (20.0% vs. 30.6%; HR 0.65; 95% CI 0.56–0.76; p < 0.001). Risks of HFE (18.4% vs. 26.9%; HR 0.69; p < 0.001), all-cause mortality (4.2% vs. 7.3%; HR 0.60; p = 0.002), and MAKE (27.5% vs. 35.1%; HR 0.81; p = 0.003) were also lower. Safety outcomes were similar, including urinary tract infection (HR 0.69; p = 0.091) and diabetic ketoacidosis (HR 1.25; p = 0.437). Conclusion SGLT2i use was associated with lower risks of cardiovascular and kidney events in patients during the chronic…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 1,318 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.